Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review-Reference-Cited by-同舟云学术

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

Published:2018-11-22 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Rochigneux Philippe^ORCID,Thomassin-Piana Jeanne,Laibe Sophy,Brunelle Serge,Salem Naji,Escudier Bernard,Vassal Gilles,Gravis Gwenaelle

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-5049-3.pdf

Reference27 articles.

1. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127–31.

2. Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Ann Oncol. 2015;26:1123–8.

3. NCCN. NCCN clinical practice guidelines in oncology-kidney cancer. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site . [cited 30 Jan 2017].

4. Appleman LJ. MET signaling pathway: a rational target for cancer therapy. J Clin Oncol. 2011;29:4837–8.

5. Petrini I. Biology of MET: a double life between normal tissue repair and tumor progression. Ann Transl Med. 2015;3:82.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MET Oncogene Targeting for Cancer Immunotherapy;International Journal of Molecular Sciences;2024-06-01

2. Peritoneal carcinomatosis of a cystic papillary renal cell carcinoma following intraoperative cyst rupture during partial nephrectomy: A case report and review of the literature;Current Problems in Cancer: Case Reports;2022-12

3. Case report: Prompt response to radiotherapy and chemotherapy combined with crizotinib in gingival sarcomatoid squamous cell carcinoma with MET 14 mutation;Frontiers in Oncology;2022-09-06

4. Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells;Pharmaceuticals;2021-11-05

5. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma;Clinical Cancer Research;2021-07-14